N4 Pharma is a specialist pharmaceutical company developing a novel silica nanoparticle (SiNP) delivery system that is initially being directed towards pDNA/mRNA delivery in oncology. N4 Pharma listed on AIM in 2016 and is managed by an experienced team of scientists and business executives with significant know-how gained both in big pharma and other smaller, specialist pharma/biopharma discovery and development enterprises.
Authors
Nigel Theobald
CEONigel has over 25 years’ experience in healthcare and in building businesses, strategy development and its implementation and a strong network covering all aspects of pharmaceutical product developm...
